Publication

Beyond Documentation: Solving the Tacit Knowledge Gap in Pharmaceutical Tech Transfer: This article discuss why Your Documentation Is Not Enough and How to Institutionalize Expert Know-How. Visit us for more…

The Algorithm of Biopharma Compliance in Canada : Navigating Health Canada’s AI Regulatory Shift In the fast-evolving landscape of Canadian life sciences where “innovation” is no longer just about the molecule. It’s about the machine.

How to Maximize Compliance in 2026 with AI-Assisted APQR Products. Discover how to leverage low-code apps for data integrity in the 2026 Compliance Revolution and enhance your APQR process to take advantage of AI-Assisted Products.

Embrace eBMR : 3 Key elements to Meeting Global Pharma Regulations – EU Annex 11; 21 CFR 11; Data Integrity – The core purpose of The Digital Imperative relating to eBMR application is to document every step of the manufacturing process

Navigating the Pitfalls of MSAT for Successful Technology Transfer: In the biopharmaceutical sector, MS&T responsibilities extend to both upstream and downstream processes. This includes optimizing cell culture conditions, managing bioreactor performance, and ensuring effective purification

Unleashing the Power of AI in BioPharma : Artificial Intelligence (AI) has the potential to transform industries, enhance efficiency, and drive innovation across various sectors, from healthcare to finance and beyond. AI is revolutionizing how we approach problems and create solutions.

FDA regulation of Artificial Intelligence (AI) and Machine Learning (ML) follows a risk-based framework focused on safety and effectiveness throughout the product lifecycle. As of mid-2025, the FDA has authorized over 1,250 AI-enabled medical devices, with nearly 80% used in radiology .

The pharmaceutical industry stands at a crossroads where regulatory expectations continue to evolve, patient safety remains paramount, and competitive pressures demand operational excellence. In this complex landscape, organizations …

The Raw Material Risks You Can’t Afford to Ignore: Ignoring raw material risks like unpredictable supply chains, political upheaval, or dwindling resource can seriously disrupt production, drive up costs, and weaken a company’s ability to bounce back.